Answers are grounded in this paper and cite their sources.
Background: Intracranial hemorrhage (ICH) is common in infants with hemophilia. We evaluated 15 children with severe hemophilia A who were initiated on emicizumab prophylaxis in infancy at the Pediatric Coagulation Center in Dublin, Ireland. Observations: The median age at emicizumab initiation was 13 weeks (range, 1 to 38 wk), and in 9 children diagnosed in the first week of life, it was 5 weeks (range, 1 to 16 wk). After a median follow-up of 36.3 months (15.6 to 55.75), no child developed ICH or spontaneous bleeding. Conclusions: Emicizumab prophylaxis in early infancy is safe and effective in the prevention of ICH and spontaneous bleeding in children with severe hemophilia A.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: